168 related articles for article (PubMed ID: 11480129)
1. Actos (pioglitazone): a new treatment for type 2 diabetes.
Lawrence JM; Reckless JP
Hosp Med; 2001 Jul; 62(7):411-6. PubMed ID: 11480129
[TBL] [Abstract][Full Text] [Related]
2. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
3. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
King AB
Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
[No Abstract] [Full Text] [Related]
4. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Jun JK; Gong WC; Mathur R
Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
[No Abstract] [Full Text] [Related]
5. Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes.
Shimono D; Kuwamura N; Nakamura Y; Koshiyama H
Diabetes Care; 2001 May; 24(5):971. PubMed ID: 11347775
[No Abstract] [Full Text] [Related]
6. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
[No Abstract] [Full Text] [Related]
9. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.
Tan MH; Johns D; Glazer NB
Clin Chem; 2004 Jul; 50(7):1184-8. PubMed ID: 15117857
[TBL] [Abstract][Full Text] [Related]
10. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
King AB; Armstrong DU
Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
14. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E; Hosaka D; Imai Y; Kawazu S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
[No Abstract] [Full Text] [Related]
17. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Nakamura T; Ushiyama C; Osada S; Shimada N; Ebihara I; Koide H
Ren Fail; 2001 Nov; 23(6):863-4. PubMed ID: 11777327
[No Abstract] [Full Text] [Related]
18. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Khan MA; St Peter JV; Xue JL
Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.
Dobiásová M
Clin Chem; 2004 Jul; 50(7):1113-5. PubMed ID: 15229146
[No Abstract] [Full Text] [Related]
20. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
LaCivita KA; Villarreal G
Curr Med Res Opin; 2002; 18(6):363-70. PubMed ID: 12442884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]